Writing in a viewpoint in JAMA, Walid F. Gellad, MD, MPH, and Chester B. Good, MD, MPH, both of the University of Pittsburgh, argue that the deep cost savings achieved in Europe for biosimilar adalimumab are unavailable to the United States because of settlements struck between AbbVie and the developers of all FDA-approved biosimilars.
In a climate of growing scrutiny of potential “pay-for-delay” patent litigation settlements, as well as antitrust lawsuits related to settlements concerning AbbVie’s blockbuster Humira, drug makers have been pushing back against suggestions that settlements made between biosimilar developers and AbbVie are harming competition in the United States.
For example, the Biosimilars Council, a part of the Association for Accessible Medicines, wrote in a white paper in June that these settlements with AbbVie—none of which will allow a biosimilar adalimumab to reach the US market before 2023—are pro-competitive in nature because they will allow biosimilars of the blockbuster therapy to reach US patients 11 years earlier than would otherwise be possible.
But not all stakeholders agree with that perspective, and this week, writing in a viewpoint in JAMA, Walid F. Gellad, MD, MPH, and Chester B. Good, MD, MPH, both of the University of Pittsburgh, argue that the deep cost savings achieved in Europe for biosimilar adalimumab are unavailable to the United States because of those very settlements struck between AbbVie and the developers of all FDA-approved biosimilars.1
By the time biosimilar adalimumab can launch in the US market, Gellad and Good write, orally administered treatments—even oral biologics—could plausibly have overtaken Humira in terms of market share, muting the effect of biosimilar entry.
If patients with inflammatory disease who currently take Humira are able to transition to more convenient options (like AbbVie’s small-molecule drug, upadacitinib) or more effective treatment options (like AbbVie’s risankizumab), they may not want to switch back to injectable adalimumab, despite the potential for reduced cost with biosimilars.
The authors predict that AbbVie will incentivize switching to its new, patent-protected agents “long before” biosimilar adalimumab becomes available, helping to ensure the company’s continued hold on the market for inflammatory diseases. They even suggest that an orally administered version of adalimumab may not be far off, which would further incentivize patients to remain on an AbbVie product rather than transition to a biosimilar.
All of these factors raise the question, say Gellad and Good, of whether the window for biosimilars to make an impact in the US market is closing.
“The example of adalimumab, including its biosimilar delay, injectable competitors, and now oral biologic competitors, should be a warning that speed is of the essence for establishing a robust biosimilar market in the United States,” they write.
Reference
1. Gellad WF, Good CB. Adalimumab and the challenges for biosimilars [published online October 23, 2019]. JAMA. doi: 10.1001/jama.2019.16275.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.